AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback